Whereas unwanted activation and expansion of CD25+ regulatory T cells (Tregs) has limited many IL-2 based immunotherapies7,39, Neo-2/15 is CD25-independent and is thus not biased to preferentially activate CD25+ Tregs22, which is one of its main advantages as a cancer therapeutic over IL-2. Here, IL2 is linked to cancer.